Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1846 to 1860 of 9102 results

  1. Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

    Awaiting development Reference number: GID-TA11828 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737]

    Awaiting development Reference number: GID-TA11965 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

    Awaiting development Reference number: GID-TA10776 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

    Technology appraisal Reference number: TA797 Published:  15 June 2022

    Technology appraisal guidance
    In development

  5. Secukinumab for treating relapsed polymyalgia rheumatica ID6599: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 22 July 2026.

    Technology appraisal guidance
    In consultation

  6. Laroprovstat for treating primary hypercholesterolaemia or mixed dyslipidaemia disease

    Awaiting development Reference number: GID-TA12477 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 March 2027

    NICE guideline
    In development

  9. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 March 2027

    NICE guideline
    In development

  10. Radiofrequency ablation of the basivertebral nerve for chronic low back pain

    Awaiting development Reference number: GID-HTG10871 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  11. Cryoablation for Desmoid-type Fibromatosis

    Awaiting development Reference number: GID-HTG10872 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Obsessive-compulsive disorder and body dysmorphic disorder

    In development Reference number: GID-QS10200 Expected publication date:  24 March 2027

    Quality standard
    In development

  13. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date:  13 January 2027

    Technology appraisal guidance
    In development

  14. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    In development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Transverse tibial transport for diabetic foot ulceration

    Awaiting development Reference number: GID-HTG10873 Expected publication date: TBC

    HealthTech guidance
    Awaiting development